A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

NCT06442436 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment (HI)

Interventions

DRUG: Nemtabrutinib

Sponsor

Merck Sharp & Dohme LLC